How can talquetamab affect exposure to medicines metabolised by CYP enzymes?

Talquetamab-induced cytokines may suppress CYP enzymes and increase CYP-substrate exposure, with greatest interaction risk from step-up initiation until 9 days after the first treatment dose and during/after cytokine release syndrome; monitor toxicity or concentrations of substrates where small changes may cause serious adverse reactions and adjust doses as needed.